Loading data
CDRENYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 610.31 m USD | 567.56 m USD | 482.53 m USD | 457.84 m USD | 427.29 m USD |
| Cost of revenue | 350.68 m USD | 334.08 m USD | 281.81 m USD | 282.16 m USD | 256.6 m USD |
| Gross profit | 259.63 m USD | 233.48 m USD | 200.73 m USD | 175.68 m USD | 170.69 m USD |
| Research and development expense | 11.4 m USD | 8.38 m USD | 6.95 m USD | 7.09 m USD | 6.46 m USD |
| Selling, general and administrative expense | 183.13 m USD | 158.32 m USD | 140.52 m USD | 153.13 m USD | 114.96 m USD |
| Operating profit | 67.35 m USD | 66.76 m USD | 56.52 m USD | 16.72 m USD | 51.72 m USD |
| Interest expense | — | — | 4.53 m USD | 6.21 m USD | 16.43 m USD |
| Profit before tax | 62.33 m USD | 54.22 m USD | 52.92 m USD | 9.37 m USD | 19.19 m USD |
| Income tax expense | 18.19 m USD | 18.09 m USD | 14.28 m USD | 3.55 m USD | 6.53 m USD |
| Net income (reported basis) | 44.14 m USD | 36.13 m USD | 38.64 m USD | 5.82 m USD | 12.66 m USD |
| Net income attributable to common shareholders | 44.14 m USD | 36.13 m USD | 38.64 m USD | 5.82 m USD | 12.66 m USD |
| Basic earnings per share | 1.08 USD/share | 0.9 USD/share | 1.03 USD/share | 0.16 USD/share | 0.44 USD/share |
| Diluted earnings per share | 1.02 USD/share | 0.9 USD/share | 1.02 USD/share | 0.16 USD/share | 0.44 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.